Log in

Relevant bibliographies by topics / Biological disease-modifying antirheumatic drugs (bDMARDs)

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'Biological disease-modifying antirheumatic drugs (bDMARDs)'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Biological disease-modifying antirheumatic drugs (bDMARDs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Biological disease-modifying antirheumatic drugs (bDMARDs)"

1

Bobkova, A. O., and A. M. Lila. "Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis." Modern Rheumatology Journal 17, no. 3 (2023): 82–88. http://dx.doi.org/10.14412/1996-7012-2023-3-82-88.

Full text

Abstract:

The goal of treatment of rheumatoid arthritis (RA) is to achieve remission or low disease activity. A wide range of disease-modifying antirheumatic drugs is used for the treatment of RA, including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). However, even with the use of bDMARDs and JAKi, this goal can be achieved only in 40–60% of patients. Insufficient response to bDMARs and JAKi is the reason for switching to other drugs from the same group, such as tumor necrosis factor-α inhibitors, and to drugs with a different mechanism of action. The ne

APA, Harvard, Vancouver, ISO, and other styles

2

Delpech, Célia, François-Xavier Larborne, and Pascal Hilliquin. "Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials." Journal of Clinical Medicine 12, no. 1 (2022): 286. http://dx.doi.org/10.3390/jcm12010286.

Full text

Abstract:

Objective: Update the available evidence comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in combination with conventional synthetic disease-modifying antirheumatic drugs (CsDMARDs) to bDMARDs in monotherapy in patients with rheumatoid arthritis. Methods: Research was limited to randomized controlled trials. Major outcome: ACR 20 response criteria at 24 weeks. Secondary outcomes: clinical and radiographic criteria at week 24, 52 and 104. Results: 23 trials (6358 patients), including seven bDMARDs and one other molecule: Anbainuo (anti-TNF-R). No study satisfied our search cri

APA, Harvard, Vancouver, ISO, and other styles

3

Batozhargalova, B. Ts, N. A. Sagatbayeva, G. M. Abdullayeva, et al. "Immunogenicity of Pneumococcal Polysaccharide Vaccine in patients with rheumatoid arthritis." Journal Infectology 16, no. 4 (2024): 36–44. http://dx.doi.org/10.22625/2072-6732-2024-16-3-36-44.

Full text

Abstract:

The presented review searched for articles in the databases PubMed, Web of Science, Scopus, Google Scholar, eLibrary (2002-2022) and assessed the immunogenicity of the 23-valent polysaccharide pneumococcal vaccine (PPV23) in adult patients with rheumatoid arthritis (RA), receiving various antirheumatic drugs. The results of this review indicated sufficient immunogenicity of PPV23 in RA patients receiving monotherapy with various biological drugs (bDMARDs) (TNFα inhibitors, IL6 receptor inhibitors, T-lymphocyte costimulation blockers), targeted synthetic disease-modifying antirheumatic drugs (t

APA, Harvard, Vancouver, ISO, and other styles

4

Natour, Abd El Haleem, and Shaye Kivity. "Biological Therapies in Inflammatory Myopathies." Rambam Maimonides Medical Journal 14, no. 2 (2023): e0008. http://dx.doi.org/10.5041/rmmj.10495.

Full text

Abstract:

Idiopathic inflammatory myopathies (IIM) are a rare group of disorders that feature progressive immune-mediated skeletal muscle destruction along with skin, lung, and joint involvement. Management of IIMs necessitates glucocorticoid therapy followed by conventional steroid-sparing agents to control disease activity. In the settings of refractory myositis or life-threatening manifestations, e.g. lung involvement or oropharyngeal dysphagia, second-line therapies are needed to minimize disease burden, avoid end-organ damage and steroid toxicity, and decrease mortality. These therapies may include

APA, Harvard, Vancouver, ISO, and other styles

5

Strong, J., T. N. Mann, G. S. Tarr, and H. Reuter. "Development of active tuberculosis in patients treated with biological disease-modifying antirheumatic drugs." South African Medical Journal 112, no. 2 (2022): 76–80. http://dx.doi.org/10.7196/samj.2022.v112i2.16036.

Full text

Abstract:

Background. Biological disease-modifying antirheumatic drugs (bDMARDs) have been shown to be highly effective in the treatment of rheumatic conditions, but may increase the risk of infections. Development of tuberculosis (TB) while on bDMARD therapy is of particular concern in high TB burden settings such as Western Cape Province, South Africa. Objectives. To describe the diagnosis, management and outcome of patients who developed active TB while receiving a bDMARD. Results. Ten patients who screened negative for TB prior to initiation of a bDMARD subsequently developed active TB. TB was diagn

APA, Harvard, Vancouver, ISO, and other styles

6

Horneff, Gerd, Julia Borchert, Joanna Diesing, et al. "Treatment Patterns in Polyarticular Juvenile Idiopathic Arthritis: A Retrospective Observational Health Claims Data Study." Life 14, no. 6 (2024): 712. http://dx.doi.org/10.3390/life14060712.

Full text

Abstract:

(1) Background: Achieving inactive disease decreases long-term joint damage in patients with polyarticular juvenile idiopathic arthritis (polyJIA). The aim of our study was to describe average time to treatment and medication changes over time. (2) Methods: Incident polyJIA patients were retrospectively identified in the InGef and WIG2 longitudinal health claims databases. Drug escalation level changes were evaluated longitudinally and cross-sectionally across three years, as follows: no treatment, glucocorticoids (GCs) and/or non-steroidal anti-inflammatory drugs (NSAIDs), conventional synthe

APA, Harvard, Vancouver, ISO, and other styles

7

Cheema, Ahmed Ammar, Amer Fakhr, Muhammad Shahid Khan, Shanzah Shahbaz, Syed Nazir Ahmed, and Muhammad Zahid Hussain. "Comparison of Respiratory Complications of COVID-19 among Patients with Rheumatological Conditions Taking Biological Disease-Modifying Anti-Rheumatic Drugs and Conventional Synthetic Disease-Modifying Antirheumatic Drugs." Pakistan Armed Forces Medical Journal 72, no. 4 (2022): 1355–58. http://dx.doi.org/10.51253/pafmj.v72i4.4498.

Full text

Abstract:

Objective: To compare the respiratory complications of COVID-19 among patients with rheumatological conditions taking bDMARDs and csDMARDs at Pak Emirates Military Hospital Rawalpindi. Study Design: Comparative prospective study. Place and Duration of Study: Pak Emirates Military Hospital, Rawalpindi Pakistan from Mar to May 2020. Methodology: Patients diagnosed with COVID-19 on polymerase chain reaction having previously rheumatological conditions managed either with bDMARD or cs DMARD were included in the study. They were followed up for three weeks after the positive polym

APA, Harvard, Vancouver, ISO, and other styles

8

Fedele, A. L., F. Melpignano, D. Bruno, R. La Ferrara, and M. A. D’agostino. "POS0662 BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS PRESCRIPTION OVER TIME IN A COHORT OF EARLY RHEUMATOID ARTHRITIS PATIENTS." Annals of the Rheumatic Diseases 81, Suppl 1 (2022): 603.2–603. http://dx.doi.org/10.1136/annrheumdis-2022-eular.5285.

Full text

Abstract:

BackgroundAccording to 2019 updated EULAR recommendations, therapy of Early Rheumatoid Arthritis (ERA) with biological disease-modifying antirheumatic drugs(bDMARDs) is adviced in presence of poor prognostic factors,i.e. persistently moderate/high disease activity, high acute phase reactants, high swollen joint count, autoantibody positivity, presence of early erosions, failure of two/more conventional synthetic DMARD.ObjectivesTo evaluate over time prevalence of bDMARD therapy and factors associated to rapid initiation in our EA Clinic (EAC), comparing two different periods: from 2004 to 2012

APA, Harvard, Vancouver, ISO, and other styles

9

Smolen, Josef S., Robert Landewé, Ferdinand C. Breedveld, et al. "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update." Annals of the Rheumatic Diseases 73, no. 3 (2013): 492–509. http://dx.doi.org/10.1136/annrheumdis-2013-204573.

Full text

Abstract:

In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and

APA, Harvard, Vancouver, ISO, and other styles

10

Gadzhanova, Svetla, and Elizabeth Roughead. "Use of Analgesic and Anti-Inflammatory Medicines before and after Initiation of Biological Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis." Journal of Clinical Pharmacy and Therapeutics 2024 (February 23, 2024): 1–7. http://dx.doi.org/10.1155/2024/8040681.

Full text

Abstract:

Background. Rheumatoid arthritis (RA) is an inflammatory condition that causes joint damage and is associated with pain. The biological disease-modifying antirheumatic drugs (bDMARDs) for RA are linked to additional therapeutic benefits as they suppress the inflammatory process, which in turn prevents joint erosion and reduces pain. Thus, the use of bDMARDs has the potential to reduce the need for other analgesic and anti-inflammatory therapies for RA. The aim of this study was to examine the analgesic and anti-inflammatory use around the initiation of bDMARDs. Methods. A cohort study was cond

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Biological disease-modifying antirheumatic drugs (bDMARDs)"

1

Yue, Xiaomeng. "Medication Patterns and Comparative Effectiveness Research of Biologic Disease-modifying Antirheumatic Drugs in Children Newly Diagnosed with Juvenile Idiopathic Arthritis using Electronic Medical Records." University of Cincinnati / OhioLINK, 2020. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1613751938659097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Oliveira, Silvia Coimbra de. "Itinerário terapêutico de pacientes com artrite reumatoide em uso de medicamentos modificadores do curso da doença biológicos." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/6/6135/tde-05012018-095623/.

Full text

Abstract:

Introdução A artrite reumatoide (AR) é uma doença crônica autoimune degenerativa, de alta prevalência e alta morbimortalidade, com difícil diagnóstico em todo o mundo. O seu pronto diagnóstico e o rápido início com medicamentos modificadores do curso da doença (MMCD) impactam de forma relevante o prognóstico do paciente. Para alguns pacientes os MMCDs sintéticos não serão eficazes e este paciente deverá receber então um MMCD biológico, medicamento este de alto custo para o paciente e o sistema de saúde. Objetivo - Explorar as trajetórias percorridas na busca por cuidado por pacientes com AR e

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Biological disease-modifying antirheumatic drugs (bDMARDs)"

1

Marshall, Tarnya, Rita Abdulkader, and Poonam Sharma. Antirheumatic drugs in pregnancy and lactation. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199642489.003.0097_update_003.

Full text

Abstract:

Antirheumatic drugs in pregnancy and lactation are increasingly a common clinical dilemma. With the shift towards early, aggressive control of autoimmune diseases and with the advent of newer therapeutic agents, there is a need to understand the effects of these medicines in pregnancy and lactation, on fertility in both men and women, and on the process of spermatogenesis, in order to understand the risk of teratogenesis. Although there are some limited data available for the use of antirheumatic drugs in pregnancy and lactation, much of our knowledge is derived from animal models and from lim

APA, Harvard, Vancouver, ISO, and other styles

2

Bissell, Lesley-Anne, Dwomoa Adu, and Paul Emery. The patient with rheumatoid arthritis, mixed connective tissue disease, Sjögren syndrome, or polymyositis. Edited by Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0166.

Full text

Abstract:

Renal disease is a well-recognized cause of ill health and death in rheumatoid arthritis. Three broad categories of renal disease occur. The first—and by far the most common—arises from the nephrotoxicity of the drugs used in the treatment of arthritis, particularly with non-steroidal anti-inflammatory drugs. Disease-modifying antirheumatic drugs such as gold and D-penicillamine may lead to proteinuria and a glomerulonephritis in 10–30% of patients. Ciclosporin is associated with significant nephrotoxicity and hypertension. A second major but diminishing cause of renal disease in rheumatoid ar

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Biological disease-modifying antirheumatic drugs (bDMARDs)"

1

"The spondyloarthritides including psoriatic arthritis." In Oxford Handbook of Rheumatology, 5th ed., edited by Gavin Clunie, Elena Nikiphorou, Nick Wilkinson, et al. Oxford University PressOxford, 2025. https://doi.org/10.1093/med/9780198885153.003.0008.

Full text

Abstract:

Abstract This chapter describes spondyloarthritis (SpA) conditions: axial spondyloarthritis, including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease-related arthritis. It summarizes evidence for pathogenetic mechanisms either common to all conditions, or specific for each condition, highlights current disease classifications, and emphasizes clinical features common to all SpAs, such as inflammatory back pain and enthesitis. There is an expanded section on treatments including biologic disease-modifying antirheumatic drugs (bDMARDs; ‘biologics’)

APA, Harvard, Vancouver, ISO, and other styles

2

Clunie, Gavin, Nick Wilkinson, Elena Nikiphorou, and Deepak R. Jadon. "The spondyloarthritides including psoriatic arthritis." In Oxford Handbook of Rheumatology, edited by Gavin Clunie, Nick Wilkinson, Elena Nikiphorou, and Deepak R. Jadon. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198728252.003.0008.

Full text

Abstract:

The Oxford Handbook of Rheumatology, 4th edition, includes a chapter on spondyloarthritis (SpA) conditions. These conditions are axial spondyloarthritis, including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease-related arthritis. It summarizes evidence for pathogenetic mechanisms either common to all conditions, or specific for each condition, highlights current disease classifications, and emphasizes clinical features common to all SpAs, such as inflammatory back pain and enthesitis. There is an expanded section on treatments including biologic

APA, Harvard, Vancouver, ISO, and other styles

3

Marshall, Tarnya, Rita Abdulkader, Poonam Sharma, and Alice Malpas. "Antirheumatic drugs in pregnancy and lactation." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0097_update_004.

Full text

Abstract:

Antirheumatic drugs in pregnancy and lactation are increasingly a common clinical dilemma. With the shift towards early, aggressive control of autoimmune diseases and with the advent of newer therapeutic agents, there is a need to understand the effects of these medicines in pregnancy and lactation, on fertility in both men and women, and on the process of spermatogenesis, in order to understand the risk of teratogenesis. Although there are some limited data available for the use of antirheumatic drugs in pregnancy and lactation, much of our knowledge is derived from animal models and from lim

APA, Harvard, Vancouver, ISO, and other styles

4

Marshall, Tarnya, Rita Abdulkader, Poonam Sharma, and Alice Malpas. "Antirheumatic drugs in pregnancy and lactation." In Oxford Textbook of Rheumatology. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0097_update_005.

Full text

Abstract:

Antirheumatic drugs in pregnancy and lactation are increasingly a common clinical dilemma. With the shift towards early, aggressive control of autoimmune diseases and with the advent of newer therapeutic agents, there is a need to understand the effects of these medicines in pregnancy and lactation, on fertility in both men and women, and on the process of spermatogenesis, in order to understand the risk of teratogenesis. Although there are some limited data available for the use of antirheumatic drugs in pregnancy and lactation, much of our knowledge is derived from animal models and from lim

APA, Harvard, Vancouver, ISO, and other styles

5

Soh, May Ching, and Catherine Nelson-Piercy. "Autoimmune rheumatic disorders and vasculitis in pregnancy." In Oxford Textbook of Medicine, edited by Catherine Nelson-Piercy. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0276.

Full text

Abstract:

Autoimmune diseases affect 5–7% of people, are more common in women of childbearing age, and are frequently encountered in pregnancy. They may remit or improve during pregnancy, but can flare or present in pregnancy. Many women with autoimmune rheumatic diseases have been advised against pregnancy in the past, but this is no longer appropriate with a new generation of pregnancy-friendly disease-modifying antirheumatic drugs and biological agents that afford excellent disease control without compromising fertility. Nevertheless, many women with autoimmune rheumatic diseases are older and have m

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Biological disease-modifying antirheumatic drugs (bDMARDs)"

1

Nakajima, A., K. Terayama, M. Sonobe, et al. "AB0204 Radiographic progression of large joint damage in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs (BDMARDS) and its predictive factors: results of 3 to 4 years follow-up." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shi, Q., T. Treuer, BC Wang, et al. "SAT0720-HPR Longitudinal analysis of response, costs and resource use of patients with rheumatoid arthritis initiating biologic disease-modifying antirheumatic drugs (BDMARDS) in taiwan using the national health insurance research database." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.5315.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ribeiro, André Lucas, Virginia Carrizo Abarza, Sahil Koppikar, Dafna Gladman, Vinod Chandran, and Lihi Eder. "COMBINATION OF BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PSORIATIC ARTHRITIS." In XLI Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2024. https://doi.org/10.47660/cbr.2024.2413.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Nuñez, Dalifer Freites, Marta Redondo, Judit Font, et al. "AB0320 FATIGUE PATTERNS IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVE BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Nuñez, Dalifer Freites, Marta Redondo, Lydia Abasolo, et al. "AB0246 PREDICTORS OF FATIGUE IN RHEUMATOID ARTHRITIS PATIENTSWHO RECEIVE BIOLOGICAL AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7177.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mahlich, J., H. Kameda, and R. Sruamsiri. "THU0620 Persistence with biological disease-modifying antirheumatic drugs – a retrospective database study in japanese patients with rheumatoid arthritis." In Annual European Congress of Rheumatology, 14–17 June, 2017. BMJ Publishing Group Ltd and European League Against Rheumatism, 2017. http://dx.doi.org/10.1136/annrheumdis-2017-eular.2102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Leão, Heloísa Isabela, Maria Eduarda de Oliveira Gonçalves, Anderson Rodrigues de Almeida, et al. "COMPARISON OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS SWITCH RATES IN RHEUMATOID ARTHRITS PATIENTS: INSIGHTS FROM A PROSPECTIVE STUDY." In XLI Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2024. https://doi.org/10.47660/cbr.2024.2633.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rezende, Cristiane de Paula, Paulo Vitor Rozario da Silva, Djenane Ramalho-de-Oliveira, et al. "EXPERIENCE OF PEOPLE WITH RHEUMATOID ARTHRITIS WITH THE USE OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: A QUALITATIVE STUDY." In XLI Congresso Brasileiro de Reumatologia. Sociedade Brasileira de Reumatologia, 2024. https://doi.org/10.47660/cbr.2024.2471.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Schlager, Lukas, Michaela Loiskandl, Daniel Aletaha, and Helga Radner. "SAT0160 PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.1578.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Al Mohamad, F., V. Rios Rodriguez, H. Haibel, et al. "POS0227 CLUSTER ANALYSIS IDENTIFIES PARTICULAR PAIN PROFILES IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS RECEIVING BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS." In EULAR 2024 European Congress of Rheumatology, 12-15 June. Vienna, Austria. BMJ Publishing Group Ltd and European League Against Rheumatism, 2024. http://dx.doi.org/10.1136/annrheumdis-2024-eular.1042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!